bluebird bio Inc (BLUE) Expected to Announce Quarterly Sales of $10.33 Million
Equities research analysts expect bluebird bio Inc (NASDAQ:BLUE) to post sales of $10.33 million for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for bluebird bio’s earnings, with the lowest sales estimate coming in at $5.00 million and the highest estimate coming in at $12.00 million. bluebird bio posted sales of $4.17 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 147.7%. The business is scheduled to issue its next earnings report on Wednesday, February 20th.
According to Zacks, analysts expect that bluebird bio will report full-year sales of $44.33 million for the current financial year, with estimates ranging from $37.00 million to $48.00 million. For the next fiscal year, analysts forecast that the business will post sales of $72.97 million, with estimates ranging from $55.67 million to $121.59 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for bluebird bio.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping analysts’ consensus estimates of ($2.90) by $0.17. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The business had revenue of $11.50 million during the quarter, compared to the consensus estimate of $6.90 million. During the same period in the prior year, the firm posted ($1.73) EPS. The business’s revenue for the quarter was up 49.2% on a year-over-year basis.
In other bluebird bio news, insider Jeffrey T. Walsh sold 1,500 shares of the company’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $150.16, for a total value of $225,240.00. Following the completion of the transaction, the insider now directly owns 36,995 shares of the company’s stock, valued at approximately $5,555,169.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David Davidson sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $139.32, for a total transaction of $696,600.00. Following the completion of the transaction, the insider now directly owns 29,905 shares of the company’s stock, valued at $4,166,364.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 21,490 shares of company stock valued at $2,901,186. 3.00% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of BLUE. Stratos Wealth Partners LTD. bought a new position in shares of bluebird bio during the third quarter worth about $106,000. Belpointe Asset Management LLC bought a new position in shares of bluebird bio during the third quarter worth about $110,000. NuWave Investment Management LLC lifted its position in shares of bluebird bio by 10,811.1% during the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 973 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of bluebird bio by 635.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 997 shares during the last quarter. Finally, Tower Research Capital LLC TRC bought a new position in shares of bluebird bio during the second quarter worth about $201,000.
NASDAQ BLUE traded down $4.80 during trading hours on Monday, hitting $108.85. The company had a trading volume of 1,221,722 shares, compared to its average volume of 793,337. bluebird bio has a fifty-two week low of $100.99 and a fifty-two week high of $236.17. The company has a market cap of $6.22 billion, a P/E ratio of -14.12 and a beta of 2.37.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Featured Article: Fundamental Analysis and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.